Status:
COMPLETED
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Body Dysmorphic Disorder
Obsessive-Compulsive Spectrum Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to learn more about two different types of psychotherapy to help individuals who have body dysmorphic disorder (BDD). BDD is a severe, often chronic, and common disorder c...
Detailed Description
Body Dysmorphic Disorder (BDD) is a common and severe disorder in which a person is preoccupied by perceived defects in his or her appearance. The purpose of this research study is to learn more about...
Eligibility Criteria
Inclusion
- Outpatient men and women age 18 and older
- DSM-IV BDD or its delusional variant for at least 6 months
- BDD is the most problematic psychiatric disorder (in the patient's and clinician's opinion) and the primary reason for seeking treatment
- Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale
Exclusion
- Current clinically significant suicidality and/or score on the BDI-II suicide item (#9) \> 1
- Any clinical features requiring a higher level of care
- Mental retardation or borderline intellectual functioning (estimated IQ \< 80 on the Wechsler Abbreviated Scale of Intelligence) or dementia, brain damage, or other cognitive impairment that would interfere with ability to engage in CBT
- DSM-IV substance abuse or dependence within the past 3 months; or a positive urine drug screen for any illicit substances of abuse
- Current manic episode
- Psychotic disorder
- Borderline personality disorder
- Body image concerns accounted for by an eating disorder
- Previous treatment with \> 10 sessions of CBT for BDD
- Subjects cannot be receiving any other psychotherapy or begin such treatment during the study
- Patients can be receiving psychotropic medication if they have taken a stable dose for at least two months before the study baseline assessment and the dose remains stable during the study.
- Presence of any behavior (e.g., violence) that would interfere with full cooperation with the protocol.
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2017
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01453439
Start Date
August 1 2011
End Date
June 7 2017
Last Update
July 15 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Rhode Island Hospital
Providence, Rhode Island, United States, 02903